MELISSA YANOVER M.D.
8 Crestmoor Drive
Denver, Colorado
Phone 303-399-7454

PROFESSIONAL EXPERIENCE

2007- present	Kidney Associates of Colorado, PC 850 E. Harvard Suite 565 Denver, CO. 80210 Phone 303-777-3333 Fax 303-733-4441 Email mjyanover@gmail.com
2008- present	Medical Director FMC Stapleton Incenter Hemodialysis and Home Dialysis
2008- present	Medical Director FMC Acute Service Denver
1984-2007	Physician Western Nephrology & Metabolic Bone Disease
1997-2005	President Western Nephrology & Metabolic Bone
1997-2005	President Western Nephrology & Metabolic Bone Disease
1984-2007	Medical Director of Lakewood Davita Home Dialysis
1997-2007	Medical Director of Lakewood Davita Hemodialysis
2004-2007	Medical Executive Board Colorado Acute Care Specialty Hospital
1999-2005	Medical Director Renal Transplant Service Porter Adventist Hospital 1997-2005 Porter Transplant Physician 1987-2008
1999-2006	MAB Donor Alliance
1985-1988	Clear Creek Valley Medical Society Board of Trustees Board of Censors Chairman, Indigent Care Committee 1986-1988

1988-1994 National Kidney Foundation, Colorado Chapter
Board of Trustees 1988-1994
Executive Board 1989-1994
Chairman, Medical Advisory Board 1991-1993
Chairman, Fundraising Committee 1993-1994

1989-1995 St. Anthony Hospital Systems
Board of Trustees 1989-1991
Education Committee 1989-1992
Credentials Committee 1992-1995
Chairman 1992-1994
Medical Executive Board 1992-1994

1991-1994 Qualicenters Inc. (Dialysis Provider)
Medical Director 1991-1997
Board Member 1991-1994

EDUCATION

1969-1973 Arcadia University
Beaver College B.A./ Arcadia University
Magna cum Laude

1973-1977 University of Pittsburgh, School of Medicine M.D.
Cum Laude
AOA 1976

POST-DOCTORAL TRAINING

1977-1978 Medical Intern, Michael Reese Hospital & Medical Center
Chicago, Illinois

1978-1980 Medical Resident, Michael Reese Hospital & Medical Center
Chicago, Illinois

1980-1981	Chief Medical Resident, Michael Reese Hospital & Medical Center Chicago, Illinois
1981-1982	Clinical Nephrology Fellow, University of Colorado Health Sciences Center Denver, CO
1982-1984	Research Nephrology Fellow, University of Colorado Health Sciences Center Department of Nephrology Denver, CO
1982-1984	Research Fellow, National Jewish Hospital and Research Center Division of Basic Immunology Denver, CO

ACADEMIC APPOINTMENTS

1984-present	Assistant Clinical Professor of Medicine University of Colorado Health Sciences Center

BOARD CERTIFICATION

Diplomate, American Board of Internal Medicine - 1980
Diplomate, American Board of Internal Medicine
Subspecialty of Nephrology - 1986

LICENSURE

National Boards, 18459D - July 1, 1978
American Board of Internal Medicine - September 9, 1980
State of Colorado, 23822 - April 9, 1981
Board Certification Nephrology - November, 1986

HONORS AND AWARDS

Beaver College
Lambda Delta Alpha Honor Society
William E. Sturgeon Senior Memorial Scholar
ACS Award for Scholastic Achievement, 1973

University of Pittsburgh
Heard Senior Prize in Medicine

Michael Reese Hospital
1978 - Outstanding Intern of the Year
1980 - Norris Brookens Award Illinois Society Internal Medicine; Outstanding Resident Medicine

Selected by 5280 Magazine as one of Denver Top Docs 2000, 2002, 2003, 2004, 2005, 2007, 2008, 2010

MEMBERSHIPS

Societies:

Alpha Omega Alpha
Colorado Medical Society
Clear Creek Valley Medical Society
American Society of Nephrology
National Kidney Foundation
Society for Clinical Densitometry

PUBLICATIONS

1. Yanover MJ, Kubo RT, Grey HM: Presentation of Alloantigen by Activated B Cells. FASEB Abstract, 1983.

2. Yanover MJ, Bichet D, and Anderson RJ: Use of Diuretics in the Treatment of Patients with Cirrhosis and Ascites and the Nephrotic Syndrome. Diuretics: Pharmacology, Physiology and Clinical Use, Edited by J. Dirks and W. Sutton, Saunder Company, Chapter 9, 1986.

3. Chestnut RW, Yanover MJJ, Grey HM: B Cell Presentation to Antigen-specific T Cells vs Presentation of Ia to Alloreactive T Cells. J Cell Biochem, 13th annual UCLA Symposia, pp. 102, February 5 - March 30, 1984.

4. Gillum DM, Dixon BS, Yanover MJ, et al: The Role of Intensive Dialysis in Acute Renal Failure. Clinical Nephrology, 1986, 25(5):249-255.

5. Brent J, Yanover M, Kulig K, Rumack BH: Valproic Acid (VPA) Poisoning Treated by Hemodialysis: AAPCC Abstract, 1988.

6. Watts NB, Harris ST, Gehant HK, Wasnich RD, Miller PD, Yanover MJ, et al: Treatment of Postmenopausal Osteoporosis with Intermittent Cyclical Etidronate, with and without Phosphate. N Engl J Med 1990, 323:73-79.

7. Miller PD, Neal BJ, McIntyre DO, Yanover MJ, Anger MS, Kowalski L: Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women. Osteoporosis Int. 1919 Jun; 1(3): 171-6.

8. Gillum DM, Yanover MJ, Kuruvila KC, Dillingham MA, Hasbargen J, McIntyre DO, Anger MS, Harrison MN, Fish EM, Erickson AL, Miller PD: Bone Mineral Density (BMD) in Stable Renal Transplant (SRTx) Patients. XIIIth Annual Meeting of the North American Society for Dialysis and Transplantation, July 1994.

9. Saag, K, Emkey, R, Gruber B, Tesser J, Lane N, Yanover M, Dubris C, Freedholm D, Carofano W, Daifotis A: Alendronate for the Management of Glucocorticoid-Induced Osteoporosis: Results of the Multicenter U.S. Study: American College of Rheumatology, Washington, DC, Abstract, 1997.

10. Adachi JD, Saag KG, Yanover MJ, et al: Two year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double blind, placebo-controlled extension trial. Arthritis Rheum. 2001 Jan; 44(1):202-11.

11. Long DG, Vernon WB, Yanover MJ. Increased acute rejection among recipients of living unrelated donor compared with cadaver and living related donor transplants. Transplant Proc. 2002 Aug; 34(5):1773-4

RESEARCH GRANTS
AWARDED:

NIH Postdoctoral Research Fellowship IF32 CA-07403-01; "Recognition of B Cell Ia by Alloreactive T Cells," Period of support - July 1983 - July 1984.

Co-Investigator - National Multicenter Study on Cyclical Etidronate Therapy in Post-menopausal Osteoporosis, 1986-1995.

Consultant for Cobe Laboratories - Dialysis Research Project at Western Dialysis Center, 1988-1995.

Co-Investigator -A Multicentered, Double-Blind, Randomized Study to Investigate the Analgesic Effect of Injectable Salmon Calcitonin in Patients with Acute Pain due to Osteoporotic Vertebral Fractures, 1990-1993.

Co-Investigator - The Effect of Calcimar on Vertebral Bone Mineral Density in Patients on Chronic Glucocoticoid Therapy, 1990-1995.

Co-Investigator - An Open-Label Phase II Study to Determine the Safety and Tolerance of Risedronate in Patients with Paget's Disease of Bone, 1991-1993.

Co-Investigator - A Multicentered, Double-Blind, Randomized, Study to Investigate the Efficacy of Miacalcin Nasal Spray in the Prevention of Osteoporotic Vertebral Fractures, 1991-1993.

Co-Investigator - A Double-Blind, Randomized, Placebo-Controlled Multicenter Trial to Determine the Efficacy of Intranasal Salmon Calcitonin in Early Postmenopausal Osteoporosis, 1991-1993.

Co-Investigator - Two-year Double-Blind, Placebo Controlled Investigation of the Efficacy and Safety of Three Doses of Esterified Estrogen (Estratab) on Bone Mineral Density and Parameters of Bone Metabolism in Postmenopausal Women, 1992-1993.

Co-Investigator - A Multicentered, Double-Blind, Randomized Study to Investigate the Efficacy of Miacalcin Nasal Spray in the Treatment of Steroid-Induced Osteoporosis, 1992-1995.

Co-Investigator - Effect of Controlled Mild Impact Exercise on Hip BMD, 1994-1995.

Co-Investigator - Study of Intermittent Cyclical Tiludronate Treatment of Established Postmenopausal Osteoporosis, 1992-1995.

Co-Investigator - Study of Intermittent Cyclical Tiludronate Treatment of Postmenopausal Women with Low Bone Mineral Mas and No Vertebral Fractures, 1992-1995.

Co-Investigator - A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study to Determine the Efficacy and Safety of Risedronate in Treatment of Osteopenic Postmenopausal Women, 1994-1995.

Co-Investigator - Assessment of Bone Mineral Density in Women Receiving Depo-Provera Contraceptive Injection, 1994-1995.

Co-Investigator - A Randomized, Double-Blind, Active-Controlled, Multicenter, Parallel Group Study to Determine the Efficacy and Safety of Risedronate Versus Didronel in the Treatment of Paget's Disease of Bone, 1994-1995.

Co-Investigator - A Long-Term Comparison of Raloxifene HCI, Placebo and Premarin in the Prevention of Osteoporosis in Postmenopausal, Hysterectomized Women, 1994-1995.

Co-Investigator - A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Determine the Efficacy and Safety of Risedronate in the Treatment of Osteoporosis in Elderly Women, 1994-1995.

Co-Investigator - A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial Comparing Valsartan 20mg, 80mg, 160mg and 320mg to Placebo in Patients with Essential Hypertension Followed by an Open-Label Extension of a 52 Week Duration, 1994-1996.

Principal Investigator - A 12-Month, Randomized, Double-Blind, Placebo-Controlled, Mulicenter Study to Evaluate the Safety and Efficacy of Two Doses of Oral Alendronate Sodium for the Prevention and Treatment of Glucocorticoid-Induced Bone Loss, 1994-1998.

Co-Investigator - Losartan Effectiveness and Tolerability (LET) Study: Prospective, Open-Label, Randomized Comparison of Two Treatment Regimens: Losartan Potassium or Losartan/HCTZ Versus Usual Care in Patients Being Treated for Mild to Moderate Hypertension Who Need to Switch Drug Therapy, 1995-2001.

Co-Investigator - Somatogen HPO12: An Eight Week, Randomized Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Recombinant Human Hemoglobin in Patients with End Stage Renal Disease. 1996-1997.

Principal Investigator - Merck Losartan Study: A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients with Non-insulin Dependent Diabetes Mellitus and Nephropathy. 1996 - 2002.

Co-Investigator - Sigma Tau: "Safety and Efficacy of Levocarnatine Supplementation in the End-Stage Renal Disease Patients Undergoing Maintenance Hemodialysis, 1997-1998

Principal Investigator - Safety and Efficacy of Levocarnitine Supplementation in End-Stage Renal Disease Patients Undergoing Maintenance Hemodialysis, a Multi-Center, Dose-Ranging Study, 1997 – 2001.

Co-Investigator - Quinton Mahurkar Triple Lumen Catheter Study, One Phase Randomized, Comparative Evaluation of Mahurkar Triple Lumen Catheter to Predicate Device, the Mahurkar Dual Lumen Catheter. 1997 – 2001.

Principal Investigator - Bone Care International Protocol #H-119: The Effect of Oral 1-alpha Hydroxyvitamin D2 on Elevated Blood Parathyroid Hormone Levels in Patients with Mild to Moderate Chronic Renal Failure. 1998 - 1999

Co-Investigator - HMR 4396A/3001: Safety and Efficacy of Intravenous HMR 4396 and Epogen for the Management of Anemia in Subjects with Chronic Renal Failure Requiring Dialysis. 1998-2000

Co-Investigator - VML 252/97/01: An Open-Label, Randomized, Parallel Group, Controlled Dose, Titration Study in Hemodialysis Patients to Compare the Efficacy and Safety of VML252 with No Treatment in the Control of Hyperphosphatemia. 1998-1999

Co-Investigator - Shire LAM-IV-307: A Phase III, Dose Titration, Long Term, Open-Label Study to Evaluate Safety and Efficacy of Lanthanum Carbonate in Chronic Renal Patients Receiving Hemodialysis. 1999-2002

Co-Investigator - DTI-0026/001: A Phase II, Multicenter, Double-Blind, Placebo-Controlled, Clinical Study to Determine the Effects of DTI-0026 on the Treatment of Glomerulonephritis. 2000 – 2002

Co-Investigator - Amgen NESP-990788: A Study Evaluating the Initiation and Titration of Fixed Doses of Novel Erythropoiesis Stimulating Protein (NESP) Therapy in Subjects with Chronic Renal Insufficiency. 2000-2001

Co-Investigator - Maret A17-002: A Single-Blind, Randomized, Placebo-Controlled Trial of MARstem with and Without Erythropoietin in End Stage Renal Disease Patients. 2001-2002

Co-Investigator - Alexion C99-004: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Effect of h5G.1-mAB on the Reduction of Proteinuria in Patients with Idiopathic Membranous Glomerulonephropathy. 2001-2002

Principal Investigator - Knoll PH040: Safety and Anticoagulant Effects of PEG-Hirudin in Patients on Chronic Hemodialysis. 2001 – 2001

Co-Investigator - Luitpold 1VEN99012: Comparison of Oral Iron with Intravenous Iron in Patients with Anemia of Chronic Renal Failure not on Dialysis. 2001 - 2002

Co-Investigator - Luitpold 1VEN01015: A Randomized Study to Assess the Safety and Tolerability of 200 mg and 100 mg Venofer Administered to Hemodialysis Patients. 2001 – 2002

Co-Investigator – Amgen 20000172: A Phase III Study to Assess the Efficacy and Safety of and Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated with Hemodialysis. 2002-2003

Co-Investigator – Abbott 2001-019: A Phase III, Prospective, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Determine the Safety and Efficacy of Zemplar Capsule (Dosed Three Times Weekly) in Reducing Elevated Serum Intact Parathyroid Hormone Levels in Subjects with Chronic Kidney Disease. 2002-2003

Principal Investigator – Ortho Biotech PR00-06-014: A Phase IV Prospective, Randomized, Open-Label, Multi-Center Study to Determine the Efficacy of PROCRIT in Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) in Patients with Chronic Kidney Disease. 2002-Present

Co-Investigator – Luitpold 1VEN02022: A Phase II/III Study of the Efficacy and Safety of Venofer (Iron Sucrose Injection) in Anemic patients Receiving Peritoneal Dialysis. 2002-2004

Co-Investigator – Amgen 20010240: A Phase III, Placebo controlled, Double blind, Extension Study to Access the Long-term Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease. 2002-2003.

Co-Investigator – Amgen 20020158: A Phase III, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) When Two Different Vitamin D Regimens are Used in Subjects with Hyperparathyroidism of End Stage Renal Disease. 2003-2004

Principal Investigator – Mitsubishi Pharma America, Inc. MCI-196-A01, MCI-196-A02: A Phase II, Open-Label, Randomized, Parallel, Titration Study to Determine the Safety and Efficacy of MCI-196 in Non-Diabetic End Stage Renal Disease Patients (MCI-196-A01) with Hyperphosphatemia on Chronic Hemodialysis. Extension Phase: MCI-196-A02. 2002-2004

Principal Investigator – Mitsubishi Pharma America, Inc. MCI-196-A03, MCI-196-A04: A Phase II, Open-Label, Randomized, Parallel, Titration Study to Determine the Safety and Efficacy of MCI-196 in Diabetic End Stage Renal Disease Patients (MCI-196-A03 with Hyperphosphatemia on Chronic Hemodialysis. Extension Phase: MCI-196-A04. 2002-2004

Co-Investigator – Ortho Biotech PR01-06-021: A Phase IV, Randomized, Open-label Clinical Evaluation of PROCRIT (Epoetin alfa) for Maintenance Phase Treatment of Patients with Anemia due to Chronic Kidney Disease (PROMPT). 2003-2003

Co-Investigator – Boehringer Ingelheim 502-397: A Phase IV, Prospective, Randomized, Double-blind, Double-dummy, Forced Titration Multicenter, Parallel Group, One Year Treatment Trial to Compare MICARDIS (telmisartan) 80 mg versus COZARR (losartan) 100 mg in Hypertensive Type 2 Diabetic Patients with Overt Nephropathy (AMADEO Study). 2003-2004

Co-Investigator – Nabi-1371: A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of StaphVAX, A Bivalent

Staphylococcus aureus Glycoconjugate Vaccine in Adults on Hemodialysis. 2003-2005

Co-Investigator - Amgen 20030153: A Phase III, Multicenter, Single Arm Study Evaluating Once Monthly Darbepoetin Alfa Dosing in Subjects With Chronic Kidney Disease Not Receiving Dialysis. 2004-2005

Co-Investigator - Amgen 20030237: A Phase III, Multicenter, Single Arm Study Evaluating De Novo Once Every Two Weeks Darbepoetin Alfa Dosing In Subjects With Chronic Kidney Disease Not Receiving Dialysis. 2004-2005

Principal Investigator – Roche BA16739: A Phase III, Randomized, Controlled, Open-label, Multicenter, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients with Chronic Kidney Disease who are on Dialysis. 2004-2006

Principal Investigator – Roche BA16736: A Phase III, Open-label, Randomized, Multicenter, Parallel Group Study to Demonstrate Correction of Anemia Using Intravenous Injections of RO050381 in Patients with Chronic Kidney Disease who are on Dialysis. 2004-2005

Co-Investigator – Amgen 20010184: A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). 2004- Present

Co-Investigator – Nabi – 6402: EPIC (Effect of PhosLo on Parathyroid Hormone in Chronic Kidney Disease): A Phase IV Prospective, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel Arm, Study of Calcium Acetate (PhosLo) on Parathyroid hormone (PTH) Levels in subjects with Chronic Kidney Disease. 2004-2005

Co-Investigator – Amgen 20000178: A Phase III, Randomized, double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCL in Chronic Kidney Disease Subjects with Secondary Hyperparathyroidism Not Receiving Dialysis. 2004-Present

Co- Investigator – Shire SPD405-312: A Phase IIIb, Multi-Center, Two-Cohort, Randomized Study, with an Open-Label Run-in and a Long-Term Extension Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving HemoDialysis. 2004-2005

Co-Investigator - OrthoBiotech PRO2-32-054: A Phase III, Open-Label Pilot Study to Assess Disability in Anemic Elderly Patients with Chronic Kidney Disease Receiving Procrit.(Epoetin alfa). 2005-2005.

Principal-Investigator – Roche BH18387: A Phase III, Open-Label, Multi-Center Study to Document The Efficacy, Safety and Tolerability of Long-Term Administration of RO0503821 in Patients with Chronic Renal Anemia. 2005-Present

Co- Investigator – Amgen 20040268: A Phase III, Open-Label, Single-Arm Study to Assess The Safety of Epoetin Alfa Manufactured by a Deep Tank Technology in Subjects with Chronic Kidney Disease Receiving Dialysis. 2005 –2007

Co- Investigator – Amgen 20040259: A Phase III, Randomized, Open-Label, Study to Assess the Safety of Epoetin Alfa Manufactured by Deep Tank Technology and

Epoetin alfa Manufactured by Roller Bottle Technology in Subjects with Chronic Kidney Disease Not On Dialysis. 2005- 2007

Co- Investigator – Shire SPD405-206: A Phase II, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Lanthanum Carbonate for the Reduction of Serum Phosphorous in Subjects with Stage 3 and 4 Chronic Kidney Disease who Have Elevated Serum Phosphorus Levels. 2005-2007

Co-Investigator – OrthoBiotech EPOCKD2001: A Phase II, Open-Label, Randomized Multicenter Study of the Initiation of Four Dosing Regimens of Procrit (Epoetin alfa) for the Treatment of Anemia of Chronic Kidney Disease. 2005-Present

Co-Investigator – Exelixis XL784-201: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of XL784 Administered Orally with Albuminuria due to Diabetic Nephropathy. 2006-2008

Co-Investigator – Speedel Pharma Limited SPP301CRD15: A Phase II, Randomised, Double-Blind, Placebo controlled, Parallel Group Study to Assess the Effect of the Endothelin Receptor Antagonist Avosentan on time to Doubling Serum Creatinine, End Stage Renal Disease or Death in Patients with Type 2 Diabetes Mellitus and Diabetic Nephropathy. 2006-2007

Co-Investigator – Ilypsa ILY-1201: A Phase II, Randomized, Dose-Ranging, Single-Blind, Efficacy and Tolerability Study of ILY101 in Patients with Chronic Kidney Disease with HyperPhosphatemia on Hemodialysis. 2006-2007

Co-Investigator – Johnson and Johnson Pharmaceutical Research & Development EPOAKD3001: A Phase III, Randomized, Open-Label, Multicenter Study of Epoetin Alfa Comparing Two Extended-Dosing Regimens, Once-Weekly and Every-Two-Weeks, with the Three-Times-Weekly Dosing Regimens for Initiation and Maintenance Treatment in Anemic Subjects with Chronic Kidney Disease. 2006-Present

Co- Investigator – Amgen 20050182: A Phase III, Evaluation of Cinacalcet HCL Therapy to Lower Cardiovascular Events. 2006-Present

Principal Investigator – Roche ML 20336: A Phase III, Prospective, Randomized, Open-Label, Multicenter Pharmacoeconomic Evaluation (Time and Motion) Comparing RO0503821 to Epoetin Alfa in Patients with Chronic Kidney Disease Stage V on Dialysis. 2007-2008

Principal Investigator- Roche ML 20338: A Phase III, Two-arm, Randomized, Open-Label, Multicenter Study of Safety and Efficacy of Monthly Injections of Ro050381 versus Epoetin Alfa in Peritoneal dialysis Patients who Self Inject or Receive In-Center Injections. 2007-2008